EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a public offering price of $11.00 per share.
February 1, 2021
· 5 min read